Literature DB >> 16380465

Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice.

Peggy Roestenberg1, Frans A van Nieuwenhoven, Jaap A Joles, Claudia Trischberger, Paula P Martens, Noelynn Oliver, Jan Aten, Jo W Höppener, Roel Goldschmeding.   

Abstract

Connective tissue growth factor (CTGF) is overexpressed in diabetic nephropathy (DN) and has therefore been implicated in its pathogenesis. The objective of the present study was to determine the tissue distribution of increased CTGF expression and the relationship of plasma, urinary, and renal CTGF levels to the development and severity of DN. We studied the relationship between CTGF and renal pathology in streptozotocin (STZ)-induced diabetes in C57BL/6J mice. Diabetic and age-matched control mice were killed after 1, 2, 4, and 9 wk of diabetes. In addition, key parameters of diabetes and DN were analyzed in 10-mo-old diabetic ob/ob mice and their ob/+ littermates. STZ-induced diabetic mice showed a significantly increased urinary albumin excretion after 1 wk and increased mesangial matrix score after 2 wk. Increased renal fibronectin, fibronectin ED-A, and collagen IValpha1 expression, as well as elevated plasma creatinine levels, were observed after 9 wk. After 2 wk, CTGF mRNA was upregulated threefold in the renal cortex. By 9 wk, CTGF mRNA was also increased in the heart and liver. In contrast, transforming growth factor-beta1 mRNA content was significantly increased only in the kidney by 9 wk. Renal CTGF expression was mainly localized in podocytes and parietal glomerular epithelial cells, and less prominent in mesangial cells. In addition, plasma CTGF levels and urinary CTGF excretion were increased in diabetic mice. Moreover, albuminuria strongly correlated with urinary CTGF excretion (R = 0.83, P < 0.0001). Increased CTGF expression was also demonstrated in type 2 diabetic ob/ob mice, which points to a causal relationship between diabetes and CTGF and thus argues against a role of STZ in this process. The observed relationship of podocyte and urinary CTGF to markers of DN suggests a pathogenic role of CTGF in the development of DN.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16380465     DOI: 10.1152/ajprenal.00174.2005

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  29 in total

1.  Connective tissue growth factor modulates podocyte actin cytoskeleton and extracellular matrix synthesis and is induced in podocytes upon injury.

Authors:  Rudolf Fuchshofer; Sabrina Ullmann; Ludwig F Zeilbeck; Matti Baumann; Benjamin Junglas; Ernst R Tamm
Journal:  Histochem Cell Biol       Date:  2011-08-04       Impact factor: 4.304

2.  PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease.

Authors:  Yajuan Li; Qingsong Hu; Chunlai Li; Ke Liang; Yu Xiang; Heidi Hsiao; Tina K Nguyen; Peter K Park; Sergey D Egranov; Chandrashekar R Ambati; Nagireddy Putluri; David H Hawke; Leng Han; Mien-Chie Hung; Farhad R Danesh; Liuqing Yang; Chunru Lin
Journal:  J Clin Invest       Date:  2019-02-11       Impact factor: 14.808

Review 3.  New molecular insights in diabetic nephropathy.

Authors:  Ionel Alexandru Checheriţă; Gina Manda; Mihai Eugen Hinescu; Ileana Peride; Andrei Niculae; Ştefana Bîlha; Angelica Grămăticu; Luminiţa Voroneanu; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

4.  Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.

Authors:  Sharon G Adler; Sherwyn Schwartz; Mark E Williams; Carlos Arauz-Pacheco; Warren K Bolton; Tyson Lee; Dongxia Li; Thomas B Neff; Pedro R Urquilla; K Lea Sewell
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-03       Impact factor: 8.237

Review 5.  Novel urinary biomarkers in early diabetic kidney disease.

Authors:  Atsuko Kamijo-Ikemori; Takeshi Sugaya; Kenjiro Kimura
Journal:  Curr Diab Rep       Date:  2014-08       Impact factor: 4.810

6.  Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease.

Authors:  Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2010-10-19       Impact factor: 5.782

7.  Therapeutic Modalities in Diabetic Nephropathy: Future Approaches.

Authors:  William Brian Reeves; Bishal B Rawal; Emaad M Abdel-Rahman; Alaa S Awad
Journal:  Open J Nephrol       Date:  2012-06-25

Review 8.  Vitamin D and diabetic nephropathy.

Authors:  Yan Chun Li
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

9.  Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?

Authors:  Roger M Mason
Journal:  J Cell Commun Signal       Date:  2009-02-14       Impact factor: 5.782

10.  The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.

Authors:  Tao Jiang; Zheping Huang; Yifeng Lin; Zhigang Zhang; Deyu Fang; Donna D Zhang
Journal:  Diabetes       Date:  2010-01-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.